DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth
Question
DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth
Direct answer
Operating efficiency and treatment volume stabilization expand dialysis operating margins, supporting valuation re-rating from a 12.15x Forward P/E. — bullish pressure on DVA via clinic margin expansion and multiple re-rating.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-10
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth”, revision 1, evidence through 2026-10-10. https://marketontology.com/catalysts/2026-10-10/davita-gains-as-forward-p-e-holds-at-12-15x-against-50-6-projected-eps-growth-08c31c
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| DVA | ▲Bull | 1–4 weeks | clinic margin expansion and multiple re-rating | 67 |
DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth
Operating efficiency and treatment volume stabilization expand dialysis operating margins, supporting valuation re-rating from a 12.15x Forward P/E. — bullish pressure on DVA via clinic margin expansion and multiple re-rating.
DVA trades at 12.15x Forward P/E with 50.6% quarterly EPS growth forecast.
- SourceDVA trades at 12.15x Forward P/E with 50.6% quarterly EPS growth forecast.
- TransmissionOperating efficiency and treatment volume stabilization expand dialysis operating margins, supporting valuation re-rating from a 12.15x Forward P/E.
- SummaryDaVita gained 1.26% to $179.25, outperforming the benchmark index. Consensus projects 50.60% EPS growth for the quarter and 35.16% for the full year. Shares trade at a Forward P/E of 12.15, highlighting valuation compression relative to earnings growth.
- DVADirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- DVA closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- DVA price vs. pre-event level
- DVA volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Why DaVita HealthCare (DVA) Outpaced the Stock Market Today · polygon_news · 2026-10-09
Related catalysts
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA XLV+3.45%
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoYDVA
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.